Compare Harmony Gold Mining Co. (HMY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Novo Nordisk A/S — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16.5× Harmony Gold Mining Co.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Novo Nordisk A/S for 116 Days on average.
| HMY | NVO | |
|---|---|---|
Market Cap | $10.02B | $165.31B |
Volume | 3,643,683 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $63.98 |
52-Week Low | $13.32 | $35.29 |
Typical Hold Time | 45 Days | 116 Days |
Enterprise Value | $10.07B | $179.56B |
Dividend Yield | 4.63% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.88, up 2.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 29.57% net income margin and robust revenue growth, climbing from $42.6B in 2022 to $73.9B in 2025. Recent earnings have been mixed, with two beats and two misses in the last four quarters. Analyst sentiment is cautious, with a consensus leaning heavily toward Hold.
The outlook for HMY is balanced; its low P/E of 6.02 and expansion into copper production offer value, but bearish technicals and high hold ratings suggest near-term volatility. Key risks include execution of growth projects and commodity price fluctuations, while institutional interest remains a supportive factor.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
